Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYLIA 7/7/7 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Oral contraception
Prevention of pregnancy (FDA-approved)
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (Cr Cl <30 m L/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol primarily via CYP3A4; norethindrone via reduction and sulfate conjugation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98% bound to albumin and alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.6 L/kg (range 0.4–0.8 L/kg), indicating extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 75% (range 60–85%), with food decreasing absorption by 20%.
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment guidelines available; use caution in patients with renal impairment. Contraindicated in severe renal disease or renal failure due to potential hormonal metabolism alterations.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B or C cirrhosis or active liver disease. For mild hepatic impairment (Child-Pugh A), use caution and monitor for adverse effects; no specific dose reduction established.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, same dosing as adults; safety and efficacy established in females of reproductive age.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke due to increased cardiovascular risk.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events; women over 35 who smoke should not use combination oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders risk,Cerebrovascular disease,Myocardial infarction,Hepatic neoplasia,Gallbladder disease,Hypertension,Diabetes/glucose intolerance,Headache/migraine,Bleeding irregularities
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis/thromboembolic disorders,Cerebrovascular/coronary artery disease,Known/suspected pregnancy,Undiagnosed abnormal genital bleeding,Known/suspected breast carcinoma,Hepatic adenoma/carcinoma,Jaundice/cholestatic jaundice with prior pill use,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women >35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may increase estrogen levels; avoid large amounts. Maintain consistent dietary habits to avoid hormone fluctuations.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
NYLIA 7/7/7 contains ethinyl estradiol and norethindrone. First trimester: Not associated with major teratogenic effects in humans based on epidemiological data. Second and third trimesters: Avoid use due to potential adverse effects such as fetal genital abnormalities (including hypospadias and feminization of male fetuses) and other adverse outcomes associated with sex hormone exposure during pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Ethinyl estradiol and norethindrone are excreted in breast milk in small amounts. M/P ratio not well-established; estrogens may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Alternative contraception advised.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
NYLIA 7/7/7 is contraindicated in pregnancy; no dose adjustment recommended as use should be discontinued immediately upon pregnancy diagnosis. No pharmacokinetic data to support dose changes in pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
NYLIA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Start on the first day of menstruation; no back-up contraception needed if started correctly. Missed pills increase pregnancy risk; if one pill missed, take as soon as remembered and continue pack; if two or more missed, use back-up contraception for 7 days. Monitor for thromboembolic events, especially in smokers over 35. Consider drug interactions with rifampin, anticonvulsants, and some antibiotics.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day.,If you miss a pill, follow the instructions in the package insert.,Use back-up contraception (like condoms) if you start the pack late or miss multiple pills.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical attention if you experience severe headache, chest pain, or leg swelling.,This medication does not protect against HIV or other STDs.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYLIA 7/7/7 vs AFIRMELLE, answered by our medical review team.
NYLIA 7/7/7 is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYLIA 7/7/7 and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYLIA 7/7/7 is: One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYLIA 7/7/7 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYLIA 7/7/7 is classified as Category C. NYLIA 7/7/7 contains ethinyl estradiol and norethindrone. First trimester: Not associated with major teratogenic effects in humans based on epidemiological data. Second and third t. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.